RT Journal Article
SR Electronic
T1 Skin imprints to provide noninvasive metabolic profiling of COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.17.21255518
DO 10.1101/2021.04.17.21255518
A1 Delafiori, Jeany
A1 Siciliano, Rinaldo Focaccia
A1 de Oliveira, Arthur Noin
A1 Nicolau, José Carlos
A1 Sales, Geovana Manzan
A1 Dalçóquio, Talia Falcão
A1 Busanello, Estela Natacha Brandt
A1 Eguti, Adriana
A1 de Oliveira, Diogo Noin
A1 Bertolin, Adriadne Justi
A1 dos Santos, Luiz Augusto
A1 Salsoso, Rocío
A1 Marcondes-Braga, Fabiana G
A1 Durán, Nelson
A1 Perroud, Maurício Wesley
A1 Sabino, Ester Cerdeira
A1 Reis, Leonardo Oliveira
A1 Fávaro, Wagner José
A1 Catharino, Rodrigo Ramos
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.17.21255518.abstract
AB As the current COVID-19 pandemic progresses, more symptoms and signals related to how the disease manifests in the human body arise in the literature. Skin lesions and coagulopathies may be confounding factors on routine care and patient management. We analyzed the metabolic and lipidic profile of the skin from COVID-19 patients using imprints in silica plates as a non-invasive alternative, in order to better understand the biochemical disturbances caused by SARS-CoV-2 in the skin. One hundred and one patients (64 COVID-19 positive patients and 37 control patients) were enrolled in this cross-sectional study from April 2020 to June 2020 during the first wave of COVID-19 in São Paulo, Brazil. Fourteen biomarkers were identified related to COVID-19 infection (7 increased and 7 decreased in COVID-19 patients). Remarkably, oleamide has shown promising performance, providing 79.0% of sensitivity on a receiver operating characteristic curve model. Species related to coagulation and immune system maintenance such as phosphatidylserines were decreased in COVID-19 patients; on the other hand, cytokine storm and immunomodulation may be affected by molecules increased in the COVID-19 group, particularly primary fatty acid amides and N-acylethanolamines, which are part of the endocannabinoid system. Our results show that skin imprints may be a useful, noninvasive strategy for COVID-19 screening, by electing a pool of biomarkers with diagnostic potential.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to thank the network involved in sample collection, clinical data curation and diagnosis, in special to Paulínia Municipal Hospital and Sumaré State Hospital (CAAE 31049320.7.1001.5404) for providing samples to the initial steps of method development, and Thermo Scientific and LADETEC (UFRJ) for the technology support. This work was supported by São Paulo Research Foundation (FAPESP) [2019/05718-3 to JD, 2018/10052-1 to WJF, 2020/04705-2 to JCN and TFD], and Coordination for the Improvement of Higher Education Personnel (CAPES) [88887.513974/2020-00 to ANO].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients were recruited at Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP) localized in São Paulo city in Brazil from April to June 2020. The study was conducted according to principles expressed in the Declaration of Helsinki. Ethical approval was given by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP ethics committee (CAAE 32077020.6.0000.0005), and a signed consent form was collected from participants before enrolment.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBiomarkers elucidation data through mass spectrometry is available as supporting information Pre-processed mass spectrometry data will be available at Zenodo following publication. De-identified patient information will be made available from corresponding author upon request.